Authors response to Letter re: The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP) molecular complexity and response to targeted therapy.
作者信息
Verkerk K, Voest E E
机构信息
Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands.
Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands.
出版信息
ESMO Open. 2025 Apr;10(4):104515. doi: 10.1016/j.esmoop.2025.104515. Epub 2025 Mar 19.
Abstract
摘要
相似文献
1
Authors response to Letter re: The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP) molecular complexity and response to targeted therapy.作者对关于“通路改变负荷是靶向治疗结果的泛癌决定因素：药物重新发现方案（DRUP）分子复杂性与靶向治疗反应的结果”的信件的回复
ESMO Open. 2025 Apr;10(4):104515. doi: 10.1016/j.esmoop.2025.104515. Epub 2025 Mar 19.
2
Response to: The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP).回应：通路改变负荷是靶向治疗结果的全癌决定因素：药物再发现方案（DRUP）的结果
ESMO Open. 2025 Apr;10(4):104516. doi: 10.1016/j.esmoop.2025.104516. Epub 2025 Mar 14.
3
The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP).通路改变负荷是靶向治疗结果的泛癌决定因素：药物重新发现方案（DRUP）的结果
ESMO Open. 2025 Jan;10(1):104112. doi: 10.1016/j.esmoop.2024.104112. Epub 2025 Jan 7.
4
The evolution of precision oncology: The ongoing impact of the Drug Rediscovery Protocol (DRUP).精准肿瘤学的演进：药物再发现方案（DRUP）的持续影响。
Acta Oncol. 2024 May 23;63:368-372. doi: 10.2340/1651-226X.2024.34885.
5
Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.荷兰 DRUP 和澳大利亚 MoST 试验中，细胞周期蛋白 D-CDK4/6 通路改变的晚期癌症中，帕博西尼和瑞博西尼单药治疗的临床活性有限。
Int J Cancer. 2023 Oct 1;153(7):1413-1422. doi: 10.1002/ijc.34649. Epub 2023 Jul 10.
6
Maximizing Treatment Opportunities: Assessing Protocol Waivers' Impact on Safety and Outcome in the Drug Rediscovery Protocol.最大化治疗机会：评估方案豁免对药物再发现方案安全性和结果的影响。
Clin Cancer Res. 2024 Sep 3;30(17):3937-3943. doi: 10.1158/1078-0432.CCR-23-3917.
7
Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP).曲妥珠单抗联合帕妥珠单抗治疗 HER2 扩增型晚期结直肠癌：药物再发现方案（DRUP）的结果。
Eur J Cancer. 2024 May;202:113988. doi: 10.1016/j.ejca.2024.113988. Epub 2024 Mar 7.
8
Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment.药物重探方案（DRUP）中罕见癌症患者从基于基因组学的治疗中获益。
Clin Cancer Res. 2022 Apr 1;28(7):1402-1411. doi: 10.1158/1078-0432.CCR-21-3752.
9
ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling - a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial.ProTarget：一项基于基因组分析的丹麦全国范围的靶向癌症治疗临床试验——一项全国性、2 期、前瞻性、多药物、非随机、开放性篮子试验。
BMC Cancer. 2023 Feb 22;23(1):182. doi: 10.1186/s12885-023-10632-9.
10
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs.药物再发现方案促进了现有抗癌药物的广泛应用。
Nature. 2019 Oct;574(7776):127-131. doi: 10.1038/s41586-019-1600-x. Epub 2019 Sep 30.
本文引用的文献
1
The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP).通路改变负荷是靶向治疗结果的泛癌决定因素：药物重新发现方案（DRUP）的结果
ESMO Open. 2025 Jan;10(1):104112. doi: 10.1016/j.esmoop.2024.104112. Epub 2025 Jan 7.
2
Tumour mutational burden and survival with molecularly matched therapy.肿瘤突变负荷与分子匹配治疗的生存。
Eur J Cancer. 2023 Sep;190:112925. doi: 10.1016/j.ejca.2023.05.013.
3
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study.癌症患者的分子谱分析可实现个体化联合治疗：I-PREDICT 研究。
Nat Med. 2019 May;25(5):744-750. doi: 10.1038/s41591-019-0407-5. Epub 2019 Apr 22.
Zotero 插件